Scarica l'app Stockscreener
22.62
6.61%
-1.60
Dopo l'orario di chiusura:
22.10
-0.52
-2.30%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VKTX Giù?
Forum
Previsione
Viking Therapeutics Inc Borsa (VKTX) Ultime notizie
When the Price of (VKTX) Talks, People Listen - news.stocktradersdaily.com
Viking Therapeutics to Participate at Morgan Stanley 22nd Annual Global Healthcare Conference - Quantisnow
The Smartest Biotech Stocks to Buy With $50 - The Motley Fool
Viking therapeutics director Rouan buys $29,942 in stock By Investing.com - Investing.com Canada
Viking therapeutics director Rouan buys $29,942 in stock - Investing.com India
Director Rouan Sarah Kathryn bought $29,943 worth of shares (1,240 units at $24.15) (SEC Form 4) - Quantisnow
Viking Therapeutics, Down 40%, Just Reached a New Milestone. Is the Stock a Buy Now? - Yahoo Finance
Viking Therapeutics, Inc. (VKTX) Stock Slides as Market Rises: Facts to Know Before You Trade - MSN
Viking Therapeutics stock hits 52-week low at $24.03 By Investing.com - Investing.com Australia
Viking Therapeutics stock hits 52-week low at $24.03 - Investing.com India
Viking Therapeutics (NasdaqCM:VKTX) Seals Manufacturing Deal as Stock Declines 11% Over The Past Month - Yahoo Finance
Which Healthcare Stock Is the Best Buy Right Now? - MarketBeat
A Closer Look at Viking Therapeutics's Options Market Dynamics - Benzinga
Viking Therapeutics (NASDAQ:VKTX) Trading Down 3.4%What's Next? - MarketBeat
Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet - Yahoo Finance
VKTX Finishes Enrolment in Mid-Stage Study on Oral Weight-Loss Drug - Yahoo Finance
Viking Therapeutics Skids Despite 'Rapid' Enrollment In Obesity Pill Study - Investor's Business Daily
Health Care Down as Viking Slides -- Health Care Roundup - Marketscreener.com
Viking Therapeutics Announces Completion of Enrollment in Phase - GuruFocus
Viking Therapeutics Completes Enrollment for Phase 2 Trial of Oral Obesity Tablet - Patient Care Online
Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity - MarketScreener
Major Milestone: Viking's Oral Weight Loss Drug Advances with 280-Patient Phase 2 Trial - Stock Titan
Better Stock to Buy Right Now: Viking Therapeutics vs. Eli Lilly - MSN
Viking Therapeutics, Inc. (VKTX) Rises But Trails Market: What Investors Should Know - MSN
(VKTX) Investment Analysis - Stock Traders Daily
Market Whales and Their Recent Bets on VKTX Options - Benzinga
1 Biotech Stock Down 52% That Could Soar by 233%, According to Wall Street - Yahoo Finance
Down 65% From Its 52-Week High, Is Viking Therapeutics Stock a Bargain Buy? - Nasdaq
Is Viking Therapeutics the Next Blockbuster GLP-1 Stock? - MarketBeat
Viking Therapeutics (NasdaqCM:VKTX) Soars 10% With CordenPharma Manufacturing Agreement - Yahoo Finance
Viking Therapeutics Starts Mid-Stage Study on Oral Weight-Loss Drug - MSN
Viking Therapeutics Just Inked A $150 Million Manufacturing Deal. Here's Why Shares Crumbled. - MSN
Health Care Down as Traders Seek Out Defensive Sectors -- Health Care Roundup -March 14, 2025 at 05:24 pm EDT - Marketscreener.com
Why Viking Therapeutics Inc. (VKTX) Is Skyrocketing Today? - MSN
Viking Therapeutics, Inc. (VKTX) Ascends While Market Falls: Some Facts to Note - MSN
Viking Therapeutics: No Buyout Needed Now (NASDAQ:VKTX) - Seeking Alpha
(VKTX) Long Term Investment Analysis - Stock Traders Daily
How to Play VKTX Stock Amid Manufacturing Deal With CordenPharma - Zacks Investment Research
Viking Therapeutics (NASDAQ:VKTX) Earns “Buy” Rating from HC Wainwright - Defense World
10 Stocks Skyrocketing Today - Insider Monkey
Why VKTX Stock is Moving Today - GuruFocus.com
Viking Therapeutics Secures Manufacturing Agreement with CordenPharma, Boosting Growth Prospects and Investor Appeal - TipRanks
Why Viking Therapeutics and Roche Holdings Popped Today, but Novo Nordisk Stock Dropped - Yahoo
Viking Therapeutics’ new contract is a game changer. Here’s how much money it could bring in. - MarketWatch
Behind the Scenes of Viking Therapeutics's Latest Options Trends - Benzinga
B. Riley sees two key positives in Viking manufacturing agreement - Yahoo Finance
10.70%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):